MBX Biosciences (NASDAQ:MBX) Rating Lowered to “Sell” at Wall Street Zen

MBX Biosciences (NASDAQ:MBX) was downgraded by analysts at Wall Street Zen from a “hold” rating to a “sell” rating in a note issued to investors on Monday.

A number of other equities research analysts also recently weighed in on the stock. Citigroup reiterated an “outperform” rating on shares of MBX Biosciences in a research report on Tuesday, May 12th. Barclays raised their price objective on MBX Biosciences from $66.00 to $70.00 and gave the stock an “overweight” rating in a research note on Tuesday, May 12th. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of MBX Biosciences in a report on Tuesday, April 21st. Truist Financial upped their price objective on shares of MBX Biosciences from $50.00 to $70.00 and gave the stock a “buy” rating in a research report on Monday, May 11th. Finally, Citizens Jmp raised their target price on shares of MBX Biosciences from $76.00 to $86.00 and gave the company a “market outperform” rating in a report on Tuesday, May 12th. One research analyst has rated the stock with a Strong Buy rating, nine have issued a Buy rating and two have given a Sell rating to the company. According to MarketBeat.com, the company presently has an average rating of “Moderate Buy” and an average price target of $63.00.

MBX Biosciences Price Performance

NASDAQ MBX opened at $62.92 on Monday. The firm has a 50-day moving average price of $42.96 and a two-hundred day moving average price of $36.90. MBX Biosciences has a 12-month low of $9.63 and a 12-month high of $66.55. The company has a market capitalization of $2.99 billion, a P/E ratio of -28.47 and a beta of 0.16.

Institutional Trading of MBX Biosciences

Several large investors have recently bought and sold shares of the business. GF Fund Management CO. LTD. acquired a new position in MBX Biosciences during the fourth quarter worth about $28,000. Russell Investments Group Ltd. boosted its stake in shares of MBX Biosciences by 4,131.4% in the 3rd quarter. Russell Investments Group Ltd. now owns 1,481 shares of the company’s stock valued at $26,000 after purchasing an additional 1,446 shares in the last quarter. Royal Bank of Canada grew its holdings in shares of MBX Biosciences by 59.6% during the 4th quarter. Royal Bank of Canada now owns 1,532 shares of the company’s stock valued at $49,000 after purchasing an additional 572 shares during the last quarter. Strs Ohio grew its holdings in shares of MBX Biosciences by 128.6% during the 1st quarter. Strs Ohio now owns 1,600 shares of the company’s stock valued at $48,000 after purchasing an additional 900 shares during the last quarter. Finally, California State Teachers Retirement System increased its position in MBX Biosciences by 64.7% during the 4th quarter. California State Teachers Retirement System now owns 1,754 shares of the company’s stock worth $55,000 after purchasing an additional 689 shares in the last quarter.

MBX Biosciences Company Profile

We are a clinical-stage biopharmaceutical company focused on the discovery and development of novel precision peptide therapies for the treatment of endocrine and metabolic disorders. Our company was founded by global leaders with a transformative approach to peptide drug design and development. Leveraging this expertise, we designed our proprietary Precision Endocrine Peptide™, or PEPTM, platform to overcome the key limitations of unmodified and modified peptide therapies and to improve clinical outcomes and simplify disease management for patients.